potential therapeutic agent – Page 2 – Communicable Diseases Research

Repurposing the inhibitors of COVID-19 key proteins through molecular docking approach

Research article

Published on 2021-11-012022-10-05
Journal: Process Biochemistry [Category] 신약개발,

Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents

Ephedra Sinica STAPF의 활성 성분은 ACE2와 SARS-COV-2 RBD 사이의 상호 작용을 방해합니다 : 강력한 COVID-19 치료제

Article

Published on 2021-10-052022-08-31
Journal: Journal of ethnopharmacology [Category] MERS, SARS, 치료제,

[키워드] 293T-ACE2 4-hydroxy-6-methoxyquinoline-2-carboxylic acid (PubChem CID: 22017520) 4-hydroxyquinoline-2-carboxylic acid (PubChem CID: 3845) 4,6-dihydroxyquinoline-2-carboxylic acid (PubChem CID: 440752) ACE2 ACE2-RBD activity alleviate angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Asia Asthma binding domain Calu calu-3 cells carboxylic acid carried cells Chinese Cold component Compound compounds cough COVID-19 COVID-19 therapeutic agent Deterioration disrupt disrupting docking domain effort ephedra Ephedra sinica Ethanol HPLC hydrogen Hydrogen bond hydroxy indicated inhibit inhibit SARS-CoV-2 inhibiting Inhibition assays inhibitory activity Interaction Isolation knock-out Lung diseases material mechanism molecular docking NMR observé potent potential therapeutic agent potential therapeutic agents PPI PPI inhibitor Prevent protein-protein interaction provided pseudoviruses PubChem quinoline Quinoline-2-carboxylic acid S protein SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S protein SARS-CoV-2 virus SARS-CoV-2 virus infection Spike protein SPR Structure structures suggested surface plasmon surface plasmon resonance Symptom TCM the SARS-CoV-2 therapeutic agents these compound these compounds Traditional Chinese medicine treat viropexis virus infection were used
[DOI] 10.1016/j.jep.2021.114303 PMC 바로가기 [Article Type] Article

Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial

덱사메타손에 반응하지 않는 중증 COVID-19 환자 관리에서 시클로스포린과 파비피라비르의 병용 요법: 비대조 전향적 시험

Clinical Trial

Published on 2021-10-012022-09-11
Journal: International immunopharmacology [Category] SARS, 임상, 치료제,

[키워드] Antiviral calcineurin calcineurin inhibitors calculated carried characterized Ciclosporin clinical trial Combination Combined Confirmed COVID-19 patient confirmed COVID-19 patients Controlled controlled trials COVID-19 COVID-19 pandemic COVID-19 patient Dexamethasone dose Efficacy evaluate evaluated Favipiravir favorable effect ferritin Hospital stay ICU ICU admission immunomodulatory effects inhibitor Injections intensive care intensive care unit lung mechanical ventilation mortality rate Patient patients potential therapeutic agent potential therapeutic agents Prospective protocol respond Responding SARS-CoV-2 second dose significantly higher therapy Trial were assessed White blood cell White blood cells
[DOI] 10.1016/j.intimp.2021.108043 PMC 바로가기 [Article Type] Clinical Trial

Prolyl isomerase Pin1 plays an essential role in SARS-CoV-2 proliferation, indicating its possibility as a novel therapeutic target

Prolyl 이성질 효소 PIN1은 SARS-COV-2 증식에서 필수적인 역할을하며, 이는 새로운 치료 표적으로서의 가능성을 나타낸다.

Article

Published on 2021-09-172022-09-10
Journal: Scientific Reports [Category] SARS, 유전자 메커니즘, 진단,

[키워드] activate Acute promyelocytic leukemia acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added addition APL ATRA cells cellular coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CPE Culture culture medium Cytopathic effect drug Drug development expression global pandemic Infectious diseases inhibit inhibitor inhibitory effect leukemia medium molecular mechanism mRNA mRNA synthesis N protein novel Novel coronavirus novel coronavirus disease PIN1 potential therapeutic agent potential therapeutic agents proliferation Promyelocytic leukemia protein synthesis receptor reduced respiratory retinoic acid SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus siRNA suppressed Target identification therapeutic agents therapeutic target Transcription treat Viral
[DOI] 10.1038/s41598-021-97972-3 PMC 바로가기 [Article Type] Article

Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2

중증 급성 호흡기 증후군 코로나바이러스 2에서 주요 프로테아제 활성 부위의 가상 알라닌 스캔

Article

Published on 2021-09-112022-09-10
Journal: International Journal of Molecular Sciences [Category] SARS, 변종,

[키워드] active site acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alanine Amino acid amino acid residue catalytic dyad changed complex configuration conformation coronavirus coronavirus 2 COVID-19 determine drug resistance drug target Effect Glu166 HIS163 inhibitor inhibitors Ligand main protease MD simulation MD simulations molecular molecular dynamics Molecular dynamics simulation MPro mutant mutant protein mutant proteins mutated Mutation performed potential therapeutic agent potential therapeutic agents protease residue respiratory SARS-CoV-2 SARS-CoV-2 Mpro severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly Site the SARS-CoV-2 therapeutic agents virtual alanine scan whole protein
[DOI] 10.3390/ijms22189837 PMC 바로가기 [Article Type] Article

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Research article

Published on 2021-09-012022-10-05
Journal: Metabolism Open [Category] 신약개발,

[키워드] a BTK inhibitor Acalabrutinib Activation affected B cell Bruton tyrosine kinase inhibitors BTK BTK inhibitor BTK inhibitors Cancer caused clinical study Coronavirus disease 2019 COVID-19 COVID-19 infected patients database drug Elsevier English Evidence Google Scholar Host Ibrutinib include Inflammation inhibition inhibitor Lung injury Macrophage management pandemic Pathways Patient potential therapeutic agent protective effect pulmonary injury regulate searched severe COVID-19 shown Signaling small molecule survival therapeutic strategy Treatment tyrosine tyrosine kinase inhibitor Web of Science Wuhan, China
[DOI] 10.1016/j.metop.2021.100116 [Article Type] Research article

Multi-omic profiling of plasma reveals molecular alterations in children with COVID-19

혈장의 다중 생물 프로파일 링

Research Paper

Published on 2021-07-062022-09-10
Journal: Theranostics [Category] MERS, SARS, 유전자 메커니즘,

[키워드] Adults alteration Analysis Anti-inflammatory antioxidant AUC blood sample Blood samples children children with COVID-19 Cohort Combination conducted Coronaviral coronavirus disease Coronavirus disease 2019 Coronavirus infection COVID-19 demonstrated develop enrolled exhibiting experiment expression finding healthy children Hospital admission Hospital admissions identify immune Inference inhibited less machine learning mannitol mechanism metabolite metabolites metabolomic profiling methylmalonic acid Mild symptom mild symptoms molecular molecules outpatients Pathogenesis pathogenesis of COVID-19 performed plasma potential therapeutic agent potential therapeutic agents pro-inflammatory factors Protective protective effect Protective effects protective role Protein proteomic provided Replication reveal severe symptom statistical analyses suppressed therapeutic agents up-regulated
[DOI] 10.7150/thno.61832 PMC 바로가기 [Article Type] Research Paper

Exosomes contribution in COVID-19 patients’ treatment

Commentary

Published on 2021-05-312022-10-30
Journal: Journal of Translational Medicine [Category] COVID-19, SARS,

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro

새로운 가상 스크리닝 절차는 Pralatrexate를 SARS-CoV-2 RdRp의 억제제로 식별하고 시험관 내 바이러스 복제를 감소시킵니다.

Research Article

Published on 2020-12-312022-08-13
Journal: PLoS Computational Biology [Category] Biochemistry, COVID-19, SARS,

[키워드] 2019-nCoV acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alternative method alternative methods anti-viral drug applied approved drugs Azithromycin conditions coronavirus COVID-19 deep learning demonstrated develop disease drug drug candidates drug candidates targeting Drug screening drugs EC50 value EC50 values effective drug effective drugs FDA-approved drug feasibility global public health hybrid drug identify in vitro inhibit inhibit SARS-CoV-2 inhibitor inhibitors inhibitors of SARS-CoV-2 inhibitory activity lack leads molecular dynamics Molecular dynamics simulation No effective drug Novel coronavirus paper potential therapeutic agent potential therapeutic agents Pralatrexate provide RdRP reduce Remdesivir Replication respiratory RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 RdRp SARS-CoV-2 replication screening procedure selected severe acute respiratory syndrome Coronavirus Spread therapeutic agents therapeutic target threat traditional methods treat Vaccine Viral viral replication Viral RNA viral RNA-dependent RNA polymerase Virtual screening virus worldwide crisis
[DOI] 10.1371/journal.pcbi.1008489 PMC 바로가기 [Article Type] Research Article

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings

다단계, 다단계 프로토콜을 사용하는 적응형 플랫폼 시험: 전염병 상황에서 빠른 답변 얻기

Opinion Article

Published on 2020-11-232022-09-11
Journal: F1000Research [Category] MERS, 임상,

[키워드] accumulating acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive platform trial approach benefit Clinicians competing conduct conducted control arm coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 determine effective interventions efficient Epidemic FAME faster greater Health Health care Health care system health care systems help identify in-silico In-vitro inefficient Infection Interim analyses interim analysis International Intervention investigated IPD limitation majority MAMS Meta-analysis multi-arm multi-stage not used overcome pandemic Pandemics patients platform Platform trial potential therapeutic agent potential therapeutic agents Potential treatment promise provide Randomised clinical trials recruitment respiratory SARS-CoV-2 Sequencing severe acute respiratory syndrome Coronavirus significantly solution Standard-of-care subsequent therapeutic agents Treatment Trial trials Two-arm Vaccinations well
[DOI] 10.12688/f1000research.26253.2 PMC 바로가기 [Article Type] Opinion Article